Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Arcellx, Inc.
Arcellx, Inc.
University of Kansas Medical Center
Zhujiang Hospital
Ryvu Therapeutics SA
Centre Hospitalier Universitaire de Besancon
Guangzhou Lupeng Pharmaceutical Company LTD.
Ascentage Pharma Group Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NexImmune Inc.
University of Tennessee
University of Auckland, New Zealand
University of Birmingham
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Melbourne Health
Biocity Biopharmaceutics Co., Ltd.
Perseus Proteomics Inc.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
The First Affiliated Hospital of Soochow University
AB Science
The First Affiliated Hospital of Soochow University
Mabwell (Shanghai) Bioscience Co., Ltd.
Centre Hospitalier Universitaire, Amiens
The University of Hong Kong
Shenzhen Second People's Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Taiga Biotechnologies, Inc.
Chinese PLA General Hospital
Hospices Civils de Lyon
The First Affiliated Hospital of Soochow University
Gruppo Italiano Malattie EMatologiche dell'Adulto
The First Affiliated Hospital of Soochow University
Guizhou Bailing Group Pharmaceutical Co Ltd
University Hospital, Toulouse
Grupo Cooperativo de HemopatÃas Malignas
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Maxinovel Pty., Ltd.
Sun Yat-sen University
Zhengzhou University
Centre for Research and Technology Hellas
Jasper Therapeutics, Inc.
First Affiliated Hospital of Jinan University
Fred Hutchinson Cancer Center
Northwestern University
iCell Gene Therapeutics
Loyola University
University Hospital, Clermont-Ferrand
Osaka University
Associazione Italiana Pazienti Leucemia Mieloide Cronica
University of Campinas, Brazil
National Research Center for Hematology, Russia